How PBMs and Discount Cards Impact Generic Drug Prices (video)

Drug Channels

In the video below, I discuss how generic drug pricing and the rise of patient-paid, discount card prescriptions pose a risk to pharmacy benefit plans and the PBM business. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc.

Strategies for Pricing Generic Drugs

Drug Patent Watch

When it comes to pricing generic drugs, there are a number of factors that come into play. In countries without drug price regulations, the pricing is based largely on profitability.….

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Medicare could save up to $3.6 billion by purchasing generic drugs at Mark Cuban prices

Scienmag

billion by purchasing generic drugs at Mark Cuban prices Abstract: [link] URL goes live when the embargo lifts A brief research report found that Medicare could have saved up to $3.6 billion by purchasing generic drugs at the same prices as the Mark Cuban Cost Plus Drug […]. Latest News billion Cuban Drugs generic mark Medicare prices purchasing saveMedicare could save up to $3.6

Development of Generic Drug Products by Pharmaceutical Industries Considering Regulatory Aspects: A Review

Drug Patent Watch

International License Abstract Development of generic drug product…. The post Development of Generic Drug Products by Pharmaceutical Industries Considering Regulatory Aspects: A Review appeared first on DrugPatentWatch - Make Better Decisions.

Finding and Evaluating Generic Drug Market Entry Opportunities

Drug Patent Watch

Here is a copy of the talk I gave at the recent Marcusevans 13th Portfolio Management and Pipeline Optimization for Generics. I cover: How to find and evaluate generic entry….

Our Generic Drug Supply Is Sick

NY Times

Drugs (Pharmaceuticals) Factories and Manufacturing Generic Brands and Products Shortages Layoffs and Job Reductions International Trade and World Market

Generic Drugs Approved but not Launched – How to Tell When Generic Drugs Will hit the Market

Drug Patent Watch

Just because a drug has received FDA approval does not mean that it is available in the marketplace. The post Generic Drugs Approved but not Launched – How to Tell When Generic Drugs Will hit the Market appeared first on DrugPatentWatch - Make Better Decisions.

Shark Tank's Mark Cuban Dives into Generic Drug Market

BioSpace

Billionaire entrepreneur Mark Cuban, best known as the owner of the Dallas Mavericks and an investor on the ABC business reality series “Shark Tank,” is diving into generic drugs with a new startup, dubbed Mark Cuban Cost Plus Drug Company

FDA welcomes alternative approaches to generic drug development

The Pharma Data

FDA officials said that the number of a product specific guidances (PSGs) issued by the Office of Generic Drugs (OGD) has increased steadily since FY 2013. FDA webinar on product specific guidance for generic drugs .

Bloomberg and Drug PatentWatch: A “Perfect Storm” Affecting Generic Drugs

Drug Patent Watch

This likely means fewer generic entrants and less opportunities for consumers to enjoy…. The post Bloomberg and Drug PatentWatch: A “Perfect Storm” Affecting Generic Drugs appeared first on DrugPatentWatch - Make Better Decisions.

Canada Generic Drug Market Industry Trends, Share, Size, Growth, Opportunity and Forecasts 2021-2026 – ResearchAndMarkets.com

BioTech 365

Canada Generic Drug Market Industry Trends, Share, Size, Growth, Opportunity and Forecasts 2021-2026 – ResearchAndMarkets.com Canada Generic Drug Market Industry Trends, Share, Size, Growth, Opportunity and Forecasts 2021-2026 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Canada Generic Drug Market: Industry Trends, Share, Size, … Continue reading → Business Wire

Global Generic Drugs Market Report 2021: The New Generics Era – The Patent Cliff, Types of Generic Drugs, Simple Generics, Super Generics, Biosimilars, ANDA Approvals – ResearchAndMarkets.com

BioTech 365

Global Generic Drugs Market Report 2021: The New Generics Era – The Patent Cliff, Types of Generic Drugs, Simple Generics, Super Generics, Biosimilars, ANDA Approvals – ResearchAndMarkets.com Global Generic Drugs Market Report 2021: The New Generics Era – The Patent … Continue reading → Business Wire

Brazil Generic Drug Market (2021 to 2026) – Industry Trends, Share, Size, Growth, Forecast and Opportunities – ResearchAndMarkets.com

BioTech 365

Brazil Generic Drug Market (2021 to 2026) – Industry Trends, Share, Size, Growth, Forecast and Opportunities – ResearchAndMarkets.com Brazil Generic Drug Market (2021 to 2026) – Industry Trends, Share, Size, Growth, Forecast and Opportunities – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Brazil Generic … Continue reading → Business Wire

GCC Generic Drug Market Trends, Share, Size, Opportunity and Forecasts 2021-2026 – ResearchAndMarkets.com

BioTech 365

GCC Generic Drug Market Trends, Share, Size, Opportunity and Forecasts 2021-2026 – ResearchAndMarkets.com GCC Generic Drug Market Trends, Share, Size, Opportunity and Forecasts 2021-2026 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “GCC Generic Drug Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast … Continue reading → Business Wire

Sandoz Resolves Legacy Federal Government Civil Investigation in the U.S. Regarding Generic Drugs

BioTech 365

Regarding Generic Drugs Sandoz Resolves Legacy Federal Government Civil Investigation in the U.S. Regarding Generic Drugs Company previously disclosed settlement agreement in principle and fully provisioned for this resolution Basel, … Continue reading → GlobeNewswireSandoz Resolves Legacy Federal Government Civil Investigation in the U.S.

This New Year, SMB Generic Drug Manufacturers Take Back Control with MDH Insight’s Trailblazing EmpowerRM® Pharma Chargeback Software

BioTech 365

This New Year, SMB Generic Drug Manufacturers Take Back Control with MDH Insight’s Trailblazing EmpowerRM® Pharma Chargeback Software This New Year, SMB Generic Drug Manufacturers Take Back Control with MDH Insight’s Trailblazing EmpowerRM® Pharma Chargeback Software PEMBROKE PINES, Fla.–(BUSINESS

Demand Management Solution Helps a Generic Drugs Manufacturer Reduce Costs and Address Supply Chain Complexities | Infiniti’s Recent Client Engagement

BioTech 365

Sponsored | China’s Establishing Patent Linkage System More Favorable to Generic Drug Companies o.

BioSpace

For the medical industry, China's proposed patent linkage system can be more favorable to generic drug companies than the U.S. The fourth Amendment of the China Patent Law has been deliberated and was passed on October 17, 2020. It will come into force on June 1, 2021. system

United States Drug Patent Prices Database 2021: Brand vs. Generic Drug Price Gap, find generic entry opportunities – ResearchAndMarkets.com

BioTech 365

United States Drug Patent Prices Database 2021: Brand vs. Generic Drug Price Gap, find generic entry opportunities – ResearchAndMarkets.com United States Drug Patent Prices Database 2021: Brand vs. Generic Drug Price Gap, find generic entry opportunities – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The … Continue reading → Business Wire

United States Generic Drugs Market Report 2020-2026: Focus on CNS, Cardiovascular, Dermatology, Genitourinary/Hormonal, Respiratory, Anti-infective & Oncology – ResearchAndMarkets.com

BioTech 365

United States Generic Drugs Market Report 2020-2026: Focus on CNS, Cardiovascular, Dermatology, Genitourinary/Hormonal, Respiratory, Anti-infective & Oncology – ResearchAndMarkets.com United States Generic Drugs Market Report 2020-2026: Focus on CNS, Cardiovascular, Dermatology, Genitourinary/Hormonal, Respiratory, Anti-infective & Oncology – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The … Continue reading → Business Wire

Drug Channels News Roundup, June 2022: Drug Spending in 2021, PBM Exclusions, Employers vs. Rebates, GoodRx Questions, and More Prior Authorization Humor

Drug Channels

Through the Drug Channels Institute, I strive to provide you with fact-based and balanced coverage—along with links to source materials so you can make up your own mind. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc.

Global Generic Drugs (Small Molecule Generics vs Biosimilars) Market Forecast & Opportunities, 2021-2026 by Application, Drug Delivery, Form, Source, Distribution Channel – ResearchAndMarkets.com

BioTech 365

Global Generic Drugs (Small Molecule Generics vs Biosimilars) Market Forecast & Opportunities, 2021-2026 by Application, Drug Delivery, Form, Source, Distribution Channel – ResearchAndMarkets.com Global Generic Drugs (Small Molecule Generics vs Biosimilars) Market Forecast & Opportunities, 2021-2026 by Application, Drug Delivery, … Continue reading → Business Wire

Development of the generic drug industry in the US after the Hatch-Waxman Act of 1984

Drug Patent Watch

The post Development of the generic drug industry in the US after the Hatch-Waxman Act of 1984 appeared first on DrugPatentWatch - Make Better Decisions. This article was originally published by Garth Boehm, Lixin Yao, Liang Hana, and Qiang Zheng in Acta Pharmaceutica Sinica under a creative commons license. Abstract The key events in the….

CVS Pharmacy Downsizes: 10 Industry Trends Driving the Retail Shakeout

Drug Channels

For more on pharmacy’s future, please register for Drug Channels Outlook 2022 , my live video webinar that will air on December 17, 2021. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc.

Drug Channels News Roundup, February 2022: Mark Cuban vs. Generics, Novo Nordisk’s G2N, CVS & 340B, and My Favorite Chart

Drug Channels

Celebrate the imminent return of spring with our selection of noteworthy news from around the drug channel. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. 340B Generic Drugs Gross-to-Net Bubble

Novateur Ventures: Overlooked Generic Drug Strategy May Prevent COVID-19’s Cytokine Storm

BioSpace

Two generic anti-inflammatory drugs typically used in asthma treatments are being proposed for use with COVID-19 because of their potential to dampen disease progression and severity

Faster FDA Approvals Don’t Affect Generic Drug Availability or Cost

Pharmacy Checkers

I’m proud to share that PharmacyChecker has published a white paper that examines prices and availability of newly approved generic drugs. Our report, based on 40 generic medications that were approved from 2017-2018, clearly shows that generic drug approvals often don’t lead to greater affordability or even access here in the U.S. The KHN article concluded that the lack to generic availability in the U.S. generic for 3 of the drugs.

Comparison of Spending on Common Generic Drugs by Medicare vs Costco Members

JAMA Internal Medicine

This cross-sectional study uses 2017 and 2018 Medicare Part D clams to compare the amount Medicare pays for common generic prescriptions in Part D with prices available to patients without insurance at Costco

Kaiser Sues Merck, Generic Drug Firm Over Millions in Losses Due to Alleged "Pay-for-Delay" Scheme

BioSpace

?Kaiser Permanente has reportedly filed a lawsuit against drug maker Merck for allegedly allowing a "pay-for-delay" scheme that cost the former millions of dollars

Why GoodRx—Not Amazon—May Be the True PBM Disrupter (rerun)

Drug Channels

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Drug Channels Outlook 2022. The generic prescription market is being disrupted—but not by the big, bad spaceman from Seattle. d/b/a Drug Channels Institute.

Novartis to consider sale or separation of Sandoz business

Bio Pharma Dive

The generic drug unit has struggled in recent years, while Novartis has moved to focus more narrowly on higher-margin branded medicines

NOW AVAILABLE: The 2022 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

Drug Channels

Click here to download a free report overview (including key industry trends, the Table of Contents, and a List of Exhibits) New Drug Channels Institute Study Examines Consolidation and Vertical Integration of U.S. drug pricing, reimbursement, and dispensing system.

A Short-Term Gain for a Long-Term Loss? The Build Back Better Act’s Medicare Drug Price Negotiation Program Ignores Hatch-Waxman/BPCIA Realities. and that May Mean Big Bad Business for Generic Drug/Biosimilar Manufacturers

FDA Law Blog

5376 that has garnered the greatest amount of attention (at least in the food and drug law world) is TITLE XIII, Subtitle J (Drug Pricing), Part 1 (Lowering Prices Through Fair Drug Price Negotiation), Section 139001 (Providing for Lower Prices for Certain High-Priced Single Source Drugs).

HR 52

A Video History of Pharmacies and Prescription Prices: From Soda Fountains to GoodRx (rerun)

Drug Channels

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Drug Channels Outlook 2022. I especially enjoyed the cool visualizations of Drug Channels Institute’s industry data. from your friendly neighborhood blogger at Drug Channels.

Why GoodRx—Not Amazon—May Be the True PBM Disrupter

Drug Channels

The generic prescription market is being disrupted—but not by the big, bad spaceman from Seattle. Consequently, discount cards could become the force that upends PBMs’ pharmacy benefit economics, plan sponsors’ decisions, and the entire generic market. d/b/a Drug Channels Institute.

Detailed United States Drug Prices Database 2020 – Brand vs. Generic Drug Price – ResearchAndMarkets.com

BioTech 365

DUBLIN–(BUSINESS WIRE)–The “Drug Patent Database Subscription: US Drug Prices” database has been added to ResearchAndMarkets.com’s offering. This subscription was created to answer a simple question: When do drug patents expire? Your needs evolve as the industry keeps changing. Since then … Continue reading → Business Wire

A Video History of Pharmacies and Prescription Prices: From Soda Fountains to GoodRx

Drug Channels

Charlotte Morabito at CNBC has put together “Why Pharmacies Overcharge,” an entertaining and provocative video on the pharmacy industry and its generic prescription pricing. I especially enjoyed the cool visualizations of Drug Channels Institute’s industry data.

Anthem joins insurer-backed generics effort CivicaScript

Bio Pharma Dive

The subsidiary of hospital-owned nonprofit CivicaRx plans to make six to 10 common generic drugs that don't have enough competition to drive down cost

Drug Channels News Roundup, June 2021: Amazon's Latest, Patients vs. Accumulators, Generics & Biosimilars, 340B Games, and a Hospital Road trip

Drug Channels

As you declare your vaccinated independence, celebrate with these Drug Channels fireworks: Amazon’s teeny step toward pharmacy disruption How patients view copay accumulators My $0.02 d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc.

When FDA-Approved Generics Fail: Brand Wellbutrin XL Antidepressant is Cheaper from Canada

Pharmacy Checkers

Years ago, they took on the Food and Drug Administration in regards to Budeprion XL distributed by Teva Pharmaceuticals, the supposed generic equivalent to the popular antidepressant, Wellbutrin XL. So, what the heck happened with generic Budeprion XL? Drug Prices Generic drugs

Healthcare mergers, 'pay for delay' deals get added scrutiny under Biden order

Bio Pharma Dive

The executive order issued Friday calls on regulators to "enforce the antitrust laws vigorously" and to ban the controversial agreements that can slow the arrival of generic drugs

Employer Pharmacy Benefits 2020: Some Good Coinsurance News, But Many Still Face Prescription List Prices

Drug Channels

It’s time for our annual deep dive into employer-sponsored coverage for prescription drugs. Consistent with our previous analyses, coinsurance and deductibles remain common for specialty and fourth-tier drugs, leaving patients exposed to the undiscounted list price of their prescriptions. .

CPhI: Dramatic changes ahead for the generics market

Outsourcing Pharma

Technology impacting generic drugs include artificial intelligence, telemedicine, fraud-preventing digital solutions and more, according to a report.